SEISMIC Pharmaceuticals
Seismic Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of heart failure drug candidates acquired from Windtree Therapeutics, with a Phase 3-ready lead asset, istaroxime, for cardiogenic shock, targeting cardiology providers.
- Company typePrivate
- Founded2026
- HeadquartersDurham, United States
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What SEISMIC Pharmaceuticals does
SEISMIC Pharmaceuticals (DBA Seismic Pharma) is a privately held, clinical-stage biopharmaceutical company headquartered in Durham, United States, that was formally launched in March 2026 under the parent entity Seismic Pharmaceutical Holdings. The company is built around a portfolio of clinically validated heart failure drug candidates acquired from Windtree Therapeutics in December 2025, with its lead program istaroxime positioned as Phase 3-ready for cardiogenic shock. The portfolio targets three related indications: cardiogenic shock, acute heart failure, and advanced heart failure, all of which the company characterizes as having seen no approved medications or therapeutic advances in decades.
The company's core pipeline consists of two programs. The first is istaroxime, a Phase 3-ready drug candidate for cardiogenic shock, inherited from Windtree. The second is a next-generation oral heart failure program targeting acute and advanced heart failure, with first-in-human studies planned for 2027. Together, these assets form the development base of the company.
On the commercial side, Seismic Pharma is pre-revenue and not yet generating product sales or licensing income; revenue generation is contingent on successful clinical development and regulatory approval. The company is funded by initial financing led by Panacea Capital, with Windtree entitled to future proceeds and funding-related payments tied to the divested cardiovascular pipeline. The target end customer base, once a product is approved, is expected to be healthcare providers in cardiology, including hospitals and cardiology departments treating patients with severe heart conditions, distributed through a future licensing/royalty-oriented revenue model rather than disclosed direct sales infrastructure.
SEISMIC Pharmaceuticals firmographics
Firmographics- Name
- SEISMIC Pharmaceuticals
- Website
- https://sceismirx.com
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Short description
- Seismic Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of heart failure drug candidates acquired from Windtree Therapeutics, with a Phase 3-ready lead asset, istaroxime, for cardiogenic shock, targeting cardiology providers.
- Ownership category
- akta.pro rank
SEISMIC Pharmaceuticals industry classification
Industry- Product category
- Cardiovascular Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Lead Optimization & Preclinical Candidate Selection (HLAIALAB)
Keywords
Where SEISMIC Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Markets served
SEISMIC Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Revenue model
- Pre-revenue Stage: Seismic Pharma is a newly formed biopharmaceutical company that is pre-revenue. The company is in the clinical development stage with istaroxime being Phase 3-ready for cardiogenic shock. Revenue generation is contingent on successful clinical trials and regulatory approvals.
SEISMIC Pharmaceuticals product offering
Product offeringCore offering
SEISMIC Pharmaceuticals develops a portfolio of heart failure drug candidates acquired from Windtree Therapeutics. The lead asset istaroxime is Phase 3-ready for cardiogenic shock, and a next-generation oral heart failure program targets acute and advanced heart failure with first-in-human studies planned for 2027.
Product overview
Seismic Pharma is a biopharmaceutical company built around a portfolio of clinically validated heart failure drug candidates acquired from Windtree Therapeutics. The core offering centers on istaroxime as the Phase 3-ready lead program for cardiogenic shock, complemented by a next-generation oral heart failure program in development. Together, the portfolio addresses unmet needs across cardiogenic shock, acute heart failure, and advanced heart failure.
Differentiator
Problem solved
Functional benefit
Products and services
- istaroxime Phase 3-ready drug candidate for cardiogenic shock; the lead clinical program in SEISMIC Pharmaceuticals' cardiovascular portfolio acquired from Windtree Therapeutics.
- next-generation oral heart failure program Advancing oral heart failure drug candidate targeting acute heart failure and advanced heart failure; first-in-human studies planned for 2027.
Companies that use SEISMIC Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles1 record
SEISMIC Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
SEISMIC Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Windtree TherapeuticscoreWindtree Therapeutics divested its cardiovascular pipeline to Seismic Pharmaceutical Holdings. The portfolio includes clinically validated heart failure drug candidates, with istaroxime being Phase 3-ready for cardiogenic shock. Windtree will receive future proceeds and funding-related payments.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
SEISMIC Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- Athersys: Athersys develops cell therapy for cardiovascular indications including heart failure and acute myocardial infarction. It is an emerging player intersecting with Seismic Pharma's heart failure treatment focus, though using a different therapeutic modality.
- Mesoblast: Mesoblast develops cell-based therapies for inflammatory cardiac diseases, including advanced heart failure. It overlaps with Seismic Pharma's advanced heart failure focus using a regenerative medicine approach.
- BioCardia: BioCardia develops cell and gene therapies for cardiovascular disease, including heart failure. It is an emerging clinical-stage peer targeting similar patient populations to Seismic Pharma.
Direct peers
- Lexicon Pharmaceuticals: Lexicon Pharmaceuticals is developing sotagliflozin for heart failure and has a clinical-stage cardiovascular pipeline. It is comparable to Seismic Pharma as a clinical-stage biopharma pursuing heart failure indications.
- scPharmaceuticals: scPharmaceuticals develops Furoscix, an innovative heart failure therapy. It directly competes in the heart failure treatment space and is comparable to Seismic Pharma in size, stage, and therapeutic focus.
- Windtree Therapeutics: Windtree Therapeutics is the originator of Seismic Pharma's cardiovascular pipeline, including istaroxime. It is a clinical-stage biotech focused on cardiovascular and respiratory indications, making it the most direct historical peer in heart failure drug development.
- Tenax Therapeutics: Tenax Therapeutics is a specialty pharma company developing therapeutics for heart failure and pulmonary hypertension. It shares Seismic Pharma's clinical-stage cardiovascular focus and target indications in acute cardiac care.
- PhaseBio Pharmaceuticals: PhaseBio Pharmaceuticals is a clinical-stage biopharma developing cardiovascular therapies. It is a comparable clinical-stage peer in the cardiovascular drug development space, though now restructured.
- Cytokinetics: Cytokinetics is a late-stage clinical biopharmaceutical company developing cardiovascular medicines for heart failure, with lead programs in cardiac myosin activation. It directly parallels Seismic Pharma's focus on novel heart failure pharmacotherapy.
Broad incumbents
- AstraZeneca: AstraZeneca has a major cardiovascular franchise including heart failure drugs (e.g., dapagliflozin, sacubitril combinations). It represents a broad incumbent competitor in heart failure pharmacotherapy that Seismic Pharma would compete with commercially.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
SEISMIC Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
SEISMIC Pharmaceuticals leadership team
Management profileNumber of profiles
SEISMIC Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SEISMIC Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SEISMIC Pharmaceuticals
What does SEISMIC Pharmaceuticals do?
SEISMIC Pharmaceuticals develops a portfolio of heart failure drug candidates acquired from Windtree Therapeutics. The lead asset istaroxime is Phase 3-ready for cardiogenic shock, and a next-generation oral heart failure program targets acute and advanced heart failure with first-in-human studies planned for 2027.
Is SEISMIC Pharmaceuticals a public or private company?
SEISMIC Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was SEISMIC Pharmaceuticals founded?
SEISMIC Pharmaceuticals was founded in 2026.
Where is SEISMIC Pharmaceuticals based?
SEISMIC Pharmaceuticals is headquartered in Durham, United States, in the North America region.
How does SEISMIC Pharmaceuticals make money?
One revenue line is on record: pre-revenue Stage.
Who are SEISMIC Pharmaceuticals's main competitors?
Emerging players on record are Athersys, Mesoblast and BioCardia. Direct peers are Lexicon Pharmaceuticals, scPharmaceuticals, Windtree Therapeutics, Tenax Therapeutics, PhaseBio Pharmaceuticals and Cytokinetics. AstraZeneca is listed as a broad incumbent.
Does SEISMIC Pharmaceuticals have an API?
No public API is recorded for SEISMIC Pharmaceuticals.
What industry is SEISMIC Pharmaceuticals in?
SEISMIC Pharmaceuticals's product category is Cardiovascular Therapeutics. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 32541 and its SIC code is 2834.